Test Price
2,800 AED✅ Home Collection Available
KLF1 Gene Congenital Dyserythropoietic Anaemia Type 4 (CDA IV) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Interpretation by Specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The KLF1 Genetic Test offers definitive molecular diagnosis of Congenital Dyserythropoietic Anaemia Type 4 (CDA IV) by interrogating the full coding region of the KLF1 gene with deep next‑generation sequencing coverage. This test is the gold standard for confirming the genetic aetiology in patients with suspected congenital anaemia unresponsive to conventional therapy.
| Feature | Our KLF1 NGS Test | Sanger Single‑Gene Sequencing |
|---|---|---|
| Detection Sensitivity | 99.9% (missense, nonsense, splice, small indels) | ≈95%, may miss mosaic variants |
| Technology | Next Generation Sequencing (30× coverage) | Capillary electrophoresis – one amplicon at a time |
| Turnaround Time | 3–4 Weeks | 5–8 Weeks (fragmented workflow) |
| Bioinformatics & Reporting | ACMG classification, full clinical report | Limited; often no copy‑number analysis |
Physician Insight & Safety Protocols
“As a clinical geneticist practising under DHA licence 9294403, I understand the importance of accurate molecular diagnosis. This test provides high‑resolution evidence for precise counselling, but it must always be interpreted alongside the complete haematological phenotype. Please remember that a normal result does not exclude all forms of CDA; careful follow‑up remains essential.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Medication Warning
Do not discontinue any prescribed medication, including iron chelators, transfusions, or supportive therapies, without explicit instruction from your treating physician.
Safety & Exclusion Criteria
Exclusion Criteria for Home Blood Collection
- Haemodynamically unstable patient (hypotension, altered consciousness).
- Active bleeding or INR >3.0 with risk of uncontrolled haemorrhage.
- Severe thrombocytopenia (platelets <20 × 10⁹/L).
- Patient unable to provide informed consent (guardian required for minors).
Emergency Red Flags – Seek Immediate Medical Attention
- Acute haemolytic crisis: jaundice + dark urine + sudden pallor.
- High fever (>38.5°C) with signs of infection in a known CDA patient.
- Severe abdominal pain or splenic enlargement causing breathing difficulty.
- Loss of consciousness or extreme fatigue with heart failure symptoms.
Patient FAQ & Clinical Guidance
1. How does the KLF1 NGS test differ from a standard anaemia panel?
The KLF1 test directly sequences the gene causing Congenital Dyserythropoietic Anaemia Type 4, whereas a routine anaemia panel only measures haematological indices without genetic confirmation. This allows definitive molecular diagnosis and precise treatment guidance.
2. Is the test suitable for children, and what sample type is needed?
Yes, under documented guardian consent, a simple blood draw, extracted DNA, or one blood drop on an FTA card is sufficient — making it minimally invasive for paediatric patients. No sedation is required.
3. What does a negative result mean if my child still has symptoms?
A negative KLF1 result excludes only mutations in this gene; other congenital anaemia forms (e.g., CDA type I, II, III, or other haemolytic conditions) should be investigated through comprehensive genomic panels. A normal result does not rule out all congenital anaemias.
UAE Regulatory & Data Privacy Adherence
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – All patient data is processed under stringent encryption and access controls.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Governs secure digital health data handling.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – Ensures safety and consent protocols for all genetic testing.
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) – Consistent laboratory quality management.
Clinical & Logistical Metadata
| Test Name | KLF1 Gene Congenital Dyserythropoietic Anaemia Type 4 (CDA IV) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Full‑gene Next Generation Sequencing (30× average coverage), ACMG/AMP variant interpretation |
| ICD-10-CM Code | D64.4, Z15.89, Z13.84 |
| LOINC Code | 101606-2 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians